Arcadia Biosciences raises $4M via private placement of pre-funded warrants and options

Arcadia Biosciences, Inc.

Sold 3.88M pre-funded warrants and Series A-1/A-2 options at $1.03 per unit, gross proceeds ~$4M.
Pre-funded warrants exercisable at $0.0001; Series A-2 options at $0.91, immediately exercisable.
Series A-1 options exercisable at $0.91 after stockholder approval, expire five years later.
H.C. Wainwright acted as exclusive placement agent; 7% cash fee plus placement agent warrants.
Net proceeds to be used for working capital and general corporate purposes; offering closed June 12, 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Arcadia Biosciences, Inc. entered into Purchase Agreement with an institutional accredited investor valued at approximately $4 million (effective 2026-06-11).

Action: entry
Agreement: equity purchase
Counterparty: an institutional accredited investor
Value: approximately $4 million
Effective: 2026-06-11

Exact text from the filing

On June 11, 2026, Arcadia Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Purchaser”) for the sale and issuance in a private placement

View on SEC.gov

801 material agreements filed in the last 30 days. Browse all material agreements →

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-270560

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.